T2 Biosystems
Genomeweb has and interesting article pondering the demise of T2 Biosystems. But the story of molecular test to replace blood culture failing to gain traction doesn’t seem particularly mystifying to me.
The companies annual revenue appears to have reached ~$8M in 2024, 2023s was $7.2M so this wasn’t accelerating particularly quickly. They were operating at a loss of $50.1M in 2023, pretty typical for a startup like this. What’s a little odd is that “Cost of Product” was routinely double “product revenue”1:
Technology
T2s technology was based on detection of magnetic nano-particles. In general it appears to work as described below, do RT-PCR (on instrument) beads capture the target DNA then these DNA labelled magnetic nano-particles come in and hybridize: